May 13th 2024
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Preliminary Evidence Suggests Intermittent Dosing Can Overcome Resistance to Vemurafenib in Melanoma
July 19th 2013Using an intermittent dosing strategy with vemurafenib instead of continuous dosing has the potential to overcome the development of resistance in patients with melanoma treated with the drug.
Read More